Pharmaron, a Beijing CRO, has signed a definitive agreement to acquire a majority stake in Shin Nippon Biomedical Laboratories Clinical Pharmacology Center of Maryland. SNBL CPC, which opened in 2005, provides moderate and highly complex Phase I/II clinical development services in the University of Maryland BioPark. It has completed over 200 studies. Shin Nippon will retain a minority stake in the lab. The Maryland facility will be integrated with Pharmaron’s existing US clinical CROs in Louisville, Kentucky and Los Angeles, plus a facility in the UK.
